CLINICAL STUDIES ON TA-058, WITH SPECIAL REFERENCE TO THE TREATMENT OF RESPIRATORY TRACT INFECTIONS

Abstract

The clinical effects of TA-058 were evaluated in patients with respiratory tract infections including four cases of chronic bronchitis, two cases of bronchopneumonia and one case of bronchiectasis.
TA-058 was administered intravenously for 7-10 days at a daily dose of 1-2g. The results in this series were excellent in one case, good in three cases, fair in one case, poor in two cases. No adverse reaction due to TA-058 was clinically observed in all cases.
This results indicate usefullness of TA-058 in the treatment of respiratory tract infections.